Overexpression of HER2 occurs at the beginning of oncogenesis, indicating that HER2 is a promising real‐time prognostic marker, as its levels are correlated with the recurrence of tumours and shortening of DFP [7, 8]. The gene discussed is ERBB2; the disease is neoplasm.